Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00730_DB00851_nanopub.RAzB_OYcfohXI2sJis64ueDxnnIs-q09Fjn_sotcVRw8Q#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00730_DB00851 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00730_DB00851 label "DDI between Thiabendazole and Dacarbazine - The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Dacarbazine by decreasing Dacarbazine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Dacarbazine if Thiabendazole is initiated, discontinued or dose changed. [drugbank_resource:DB00730_DB00851]" assertion.
- drugbank_resource:DB00730_DB00851 identifier "drugbank_resource:DB00730_DB00851" assertion.
- drugbank_resource:DB00730_DB00851 title "DDI between Thiabendazole and Dacarbazine - The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Dacarbazine by decreasing Dacarbazine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Dacarbazine if Thiabendazole is initiated, discontinued or dose changed." assertion.
- drugbank:DB00851 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00730_DB00851 assertion.
- drugbank:DB00730 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00730_DB00851 assertion.